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admitted to the ICU (OR1.027, CI1.016-1.037; p.0001), and readmitted at 30
(OR1.129, CI1.118-1.141; p.0001), 90 (OR1.185, CI1.175-1.196; p.0001), and
180 (OR1.163, CI 1.153-1.173; p.0001) days post discharge compared to
non-HN patients. CONCLUSIONS: HN represents a significant clinical, utiliza-
tion, and economic burden due to increased cost, LOS, ICU admissions and
hospital readmission.
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REAL-WORLD EVALUATION OF HEALTH CARE RESOURCE UTILIZATION AND
COSTS IN PATIENTS WITH NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC
PERIPHERAL NEUROPATHY (PDPN) TREATED WITH PREGABALIN OR
GABAPENTIN
Udall M, Mardekian J, Harnett J
Pfizer, Inc., New York, NY, USA
OBJECTIVES: To evaluate and compare changes in healthcare resource utilization
and costs associated with the initiation of pregabalin or gabapentin in pDPN pa-
tients in a real-world setting.METHODS: A retrospective cohort study utilizing the
MarketScan Commercial Claims and Encounters Database (2007-2009). Patients
with a new prescription for pregabalin or gabapentin in 2008 (date of the prescrip-
tion defined as index date) and 1 healthcare encounter with an ICD-9 code for
diabetic peripheral neuropathy (DPN; 250.6 or 357.2) within 30 days prior to the first
prescription for pregabalin or gabapentin were identified and propensity score
matched. Both cohorts were continuously enrolled for the 12month pre- and post-
index periods during which health care utilization and costs were assessed. Pre- to
post-index changes were compared between pregabalin and gabapentin using a
difference-in-difference (DID) approach. RESULTS: 910 pregabalin patients (48.6%
female;mean age 63.312.1 years) werematched to 910 gabapentin patients (48.8%
female; mean age 63.312.1 years); other demographic and clinical characteristics
were also comparable between cohorts,with the exception of US region. The pre- to
post-index DID in resource utilization did not differ between the two cohorts in-
cluding: number of office visits per patient (P0.66), number of ER visits (P0.78),
number of inpatient stays (P0.92), average inpatient length of stay per hospital-
ization (P0.79), number of total prescriptions filled (P0.37). The DID of total
healthcare costs per patient were non-significant with pre- to post-index increases
of $3,081 in pregabalin patients and $4,683 in gabapentin patients (P0.50).
CONCLUSIONS: Patients with pDPN initiating pregabalin or gabapentin experi-
enced comparable changes in healthcare resource utilization and costs. These re-
sults suggest overall cost neutrality between pregabalin and gabapentin.
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FACTORS LEADING TO HIGH HEALTH CARE EXPENDITURE AMONG OBESE
INDIVIDUALS IN THE UNITED STATES
Patel JG, Aparasu RR, Rajan SS, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: To identify the factors associated with high healthcare expenditure
among obese individuals in the United States. METHODS: Analytical sample con-
sisted of obese adults 20 years or olderwith (BMI30). Total yearly expenditures for
obese adults were obtained from 2007 Medical Expenditure Panel Survey data.
Observations with total yearly healthcare expenditure greater than 90th percentile
were classified as high healthcare expenders and coded yes/no to be used as the
dependent variable. Independent factors selected according to the Anderson’s Be-
havioral Model were age, gender, race, MSA, region, education, poverty category,
source of payment, usual source of care, MSA, education, general health status,
mental health status andmortality risk status. ‘Surveylogistic’ regressionwas used
to determine the predictors of high expenditures. RESULTS: Descriptive analysis
show that adults with high healthcare expenditure were whites (74.23%), hadmid-
school education (60%), lived in MSA (79%), had usual care provider (95%), private
insurance (67%) and belonged to very high mortality risk group (46%). In adjusted
analysis, age (OR: 1.019 CI: 1.009-1.029), usual source of care (OR: 1.901 CI: 1.196-
3.020), private (OR: 3.609 CI: 1.992-6.539) and public insurance (OR: 3.251 CI: 1.781-
5.936), very high (OR: 3.342 CI: 2.327-4.798) and high (OR: 2.213 CI: 1.666-2.938)
mortality risk and general health status (OR: 2.493 CI: 2.148-2.893) were associated
with high healthcare expenditure. CONCLUSIONS: Several enabling and need fac-
tors seem to be associated with high healthcare expenditure. Both private and
public health insurance have a significant burden of healthcare expenditure asso-
ciated with obesity. Individuals with usual source of care are more likely to incur
high healthcare expenditure. Comorbidities have a significant impact on health-
care expenditure among obese individuals and highlight the need to deliver com-
prehensive disease state management. The findings from this study can have im-
portant implications in understanding increased utilization of health services
among obese adults in the United States.
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A COMPARISON OF DAILY AVERAGE SUPPLY (DASUP) OF OXYCODONE AND
OXYMORPHONE LONG-ACTING ORAL TABLETS
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OBJECTIVES: Although both oxycodone CR and oxymorphone ER are approved for
twice daily dosing, it is unclear whether actual utilization is consistent with this.
The objective was to assess whether there exist differences in the utilization of
oxycodone CR and oxymorphone ER.METHODS:We used prescription claims data
from a commercially-insured population (i3 InVision Data Mart database), during
the period January 1, 2007 to March 31, 2010. A claim for at least one 30-day supply
of study drug one month prior to the observation period was necessary to avoid
capturing utilization associated with titration. Subsequently, all subjects had a
claim for at least a 90-day supply of the respective opioid analgesic. Patients’ claims
were excluded from this analysis if there was evidence of a switch from one to the
other study opioid during the 90-day observation period. Therewere no limitations
on the use of other opioids, during the baseline or observation periods. The final
cohort consisted of 6,567 oxycodoneCRpatients and 796 oxymorphone ERpatients.
In addition to univariate analysis, multivariate analyses were conducted using
generalized linear models (GLM) to adjust for the observed heterogeneity among
patients in the observational database. RESULTS: The unadjusted daily average
supply (DASUP)mean values for the highest strengths of oxycodone CR (80mg)was
3.9 compared to 2.9 for oxymorphone ER (40mg), 3.0 vs. 2.4 for all lower strengths,
and 3.1 vs. 2.5 for all strengths. (all p0.001). After adjusting for baseline differ-
ences, a risk-adjusted overall mean difference in DASUP remainedwith oxycodone
CR patients receiving, on average, 0.6 tablets more per day than those dispensed
oxymorphone ER (p0.001). The direction, magnitude and statistical signifi-
cance of these differences were essentially unchanged in sensitivity analyses.
CONCLUSIONS: In managing the pharmacy benefit, decision-makers may want to
consider the financial implications of these DASUP differences.
Systemic Disorders/Conditions – Patient-Reported Outcomes & Preference-Based
Studies
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A REAL-WORLD EVALUATION OF ADHERENCE AND PERSISTENCE OF WEIGHT-
LOSS PHARMACOTHERAPY IN THE UNITED STATES: 2007-2010
Charland SL, Agatep BC, Aubert RE, Lazzaro J, Stanek EJ
Medco Research Institute, Medco Health Solutions, Inc, Bethesda, MD, USA
OBJECTIVES:There is a rapidly growing overweight and obesity epidemic in theUS,
and a high demand for long-term safe and effective weight-loss agents. While 3
new antiobesity therapies underwent FDA review in 2010, little is known about the
utilization of available weight-loss drugs. The objective of this analysis is to de-
scribe the real-world prescription patterns, adherence, and persistence of weight-
loss pharmacotherapy in the United States. METHODS: A retrospective cohort
analysis was conducted using Medco’s integrated claims database to evaluate
adult patients initiating weight-loss pharmacotherapy between May 2007-October
2010. Eligibility criteria included new weight-loss drug prescription claims (no
weight-loss therapy prescriptions 6 months prior to index claim date) and contin-
uous eligibility for 6months pre- and 14months post-index claim date. Patients on
drugs with 1000 distinct patient counts were analyzed for adherence (annual
Medication Possession Ratio; MPR), persistency (allowing a 45 day gap), and con-
comitant therapy. RESULTS: Analyses included 91,160 patients receiving five
drugs: phentermine (N67434), sibutramine (N13438), orlistat (N8047), phendi-
metrazine (N4631), and, diethylpropion (N 4350). MeanSD age was 4412
years (96%, 18-64 y/o), 82% were female, 46% resided in the South, and 91% filled
prescriptions at retail only. Among obesity drug prescribers with known specialty,
71% were family/internal medicine practitioners. Patients received a mean of 33
concomitant chronic medications, with 38%, 31%, 22%, and 11% on antihyperten-
sive, antidepressant, dyslipidemia, or oral antidiabetic therapy, respectively. The
mean adherence ranged fromMPR0.20 (phendimetrazine) toMPR0.26 (phenter-
mine). Persistence at 3, 6, and 12 months ranged respectively from 26%-38% (low-
phendimetrazine, high-phentermine), 9%-16% (low-phendimetrazine, high-sibut-
ramine), and 3%-6% (low-phendimetrazine, high-sibutramine). CONCLUSIONS:
Weight-loss pharmacotherapies in the United States were prescribed by primary
care physicians to predominantly younger, female patients on concomitant ther-
apy for common obesity-related conditions. Adherence and persistence to therapy
is low, even over short-term exposure, although treatment duration may extend
beyond recommendations in some cases (e.g., phentermine).
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HEMOPHILIA A: PATIENT IMPACT AND ECONOMIC BURDEN OF THE DISEASE
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OBJECTIVES:Hemophilia A is a rare but serious bleeding disorder caused by a blood
clotting factor VIII (FVIII) deficiency. To examine the impact of hemophilia A and
replacement FVIII therapies from a humanistic and economic perspective, a tar-
geted literature review was conducted. METHODS: Searches were conducted in
MEDLINE® and the National Health Service Economic Evaluation Database, using
disease, patient-reported outcome and economic-related key words, limited to
English articles published from January 2000-January 2010 (inclusive). From 653
abstracts retrieved, 34 full-text articles were selected for detailed consideration.
RESULTS: Findings revealed increased mortality rates and decreased life expec-
tancy among people with hemophilia A, compared with the general population.
This is largely attributed to the transmission of blood-borne viruses (e.g. HIV and
Hepatitis-C) due to use of plasma-derived FVIII (pdFVIII) concentrates. Improve-
ments in viral attenuation processes plus donor screening practices for pdFVIII
products have reduced the risks of viral transmission, but risk fromnon-enveloped
viruses and other unknown pathogens still exists. Newly developed recombinant
FVIII therapies minimize these risks; however, such therapies are not currently
widely available globally. All available FVIII therapies use demanding regimens
requiring regular time-consuming injections,which can be detrimental to patients’
health-related quality of life and limit adherence. Non-adherence is associated
with diminished product efficacy, poorer health outcomes and increasing eco-
nomic expenditure. Treating hemophilia A is costly, primarily due to the high
acquisition cost of replacement FVIII products. However, indirect costs (e.g. patient
disability) also contribute to economic burden. Prophylactic treatment, while ini-
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tially more expensive than on-demand treatment, is associated with greater clin-
ical efficacy and improved long-term outcomes, which may lead to cost savings
over a patient’s lifetime. CONCLUSIONS: Hemophilia A is associated with consid-
erable humanistic and economic burden. Substantial unmet needs remain among
hemophilia A patients with regard to the safety, convenience and global access to
FVIII therapy.
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HOW DO MINIMALLY IMPORTANT DIFFERENCES VALUE OUTCOMES?
Suh JK, Doctor J
USC School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: To assess the functional form of the minimally important difference
(MID)METHODS: Subjects were shown a base body weight, y1, and a current body
weight after a treatment, y2. If a subject endorsed y2 as an important difference
over y1, we denoted a pair (y2, y1). An MID is the y1 and y2 difference when the
probability of discriminating y2 fromy1was greater than 0.5. The standard formula
of this discrimination probability is given by Fechner’s Law: P(y2, y1)  F(U(y2) -
U(y1)) where F is an increasing function and U is a MID function. When the proba-
bility of discrimination is constant over proportional changes in weight (i.e., We-
ber’s Law: P(y2, y1)  P(y2, y1)), the utility function for health states is a log
function. To assess the functional form of U, we tested a hypothesis of P(y2, y1) 
P(y2, y1) 0.5. An on-line survey was conducted with three base weights: 29, 36,
and 43 lb overweight. One-way repeated measure analysis of variance (Wilk’s test)
and one-way within subjects analysis were used. RESULTS: A total of 131 subjects
participated. ThemeanMID values were 9.391 (SD 4.001), 11.195 (SD 5.236), and
13.073 (SD  6.491) for 29, 36, and 43 lb overweight, respectively. The normalized
mean MID values were 0.323 (SD  0.138), 0.311 (SD 0.145), and 0.304 (SD  0.151)
for 29, 36, and 43 lb overweight, respectively. The results of Wilk’s test was not
statistically significant (p  0.2807) Moreover, one-way within subjects resulted in
no effect of the different body weights on theMIDs at the significance level 0.01.
CONCLUSIONS: The normalized mean MIDs from three different body weights
were not statistically different. Within the limited range studied MIDs fit a log
utility model. Thus, MIDs may be problematic as a prescriptive policy tool.
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EXPLORING THE FACTOR STRUCTURE OF THE PROMIS FATIGUE ITEM BANK IN
PATIENTS WITH FIBROMYALGIA
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OBJECTIVES: The NIH roadmap project “Patient-Reported OutcomesMeasurement
Information System” (PROMIS) provides a basis for measuring symptoms - includ-
ing fatigue; associated with chronic diseases. However, information on use of PRO-
MIS with Fibromyalgia (FM) patients is limited. This study sought to evaluate the
factor structure of the 95-item PROMIS Fatigue item bank among individuals with
FM. It is unknown whether the conceptual structure of fatigue experience (inten-
sity, frequency, and duration) and impact (physical and mental) will be supported
in individuals with FM.METHODS: An internet-based survey was conducted with
individuals with FM. Participants had to be 18 years and diagnosed with FM by a
physician. Respondents were randomized into one of three cohorts, each of which
completed one-third of the 95-items from the entire PROMIS v1.0 Fatigue ItemBank
(www.nihpromis.org). Items were balanced between cohorts. Item factor analysis
was performed using both a polychoric correlation matrix with Mplus and a full-
information approach using ORDFAC. Comparisons were made using the Akaike
Information Criteria (AIC) and Bayesian Information Criterion (BIC). Models chosen
based on BIC produced interpretable factors for assessment of the PROMAX rotated
factor loadings. RESULTS: 1,207 respondents completed the survey. Mean age of
the respondents was 52.1 years. Mean time since FM diagnosis was 8.7 years. All
groups produced factor structures that included 3 factors. The first consisted
mainly of Fatigue Experience items. The second consisted mainly of items related
to Mental Impact and the third consisted of General Impact items. An additional
factor related to Social Impact was identified in Group B only. CONCLUSIONS: For
individuals with FM, the PROMIS Fatigue item bank appears to contain a factor
structure that is consistent with the original PROMIS conceptual model. Subscales
from the PROMIS Fatigue item bank can likely be used to separate Fatigue Experi-
ence from General and Mental impacts of Fatigue.
PSY34
CALCULATING PROMIS FATIGUE ITEM BANK IRT PARAMETER ESTIMATES
SPECIFIC TO PATIENTS WITH FIBROMYALGIA
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OBJECTIVES: The NIH roadmap project “Patient-Reported OutcomesMeasurement
Information System” (PROMIS) provides a basis for measuring symptoms - includ-
ing fatigue; associatedwith chronic diseases. However, information on use of PROMIS
with Fibromyalgia (FM) patients is limited. This study sought to re-estimate the
Item Response Theory (IRT) item parameter estimates for each of the 95-items
included in the PROMIS Fatigue item bank using responses from individuals with
FM. It is unknown whether the parameter estimates differ among a sample of FM
patients from that of the broader population used in the initial PROMIS item
calibrations.METHODS:An internet-based survey was conducted with individuals
with FM. Participants had to be 18 years and diagnosed with FM by a physician.
Respondents were randomized into one of three cohorts, each of which completed
one-third of the 95-items from the entire PROMIS v1.0 Fatigue ItemBank (www.nih-
promis.org). IRT model fitting of Samejima’s Graded Response Model (GRM) was
conducted using MULTILOG7 to determine item parameter estimates and com-
pared with standard PROMIS parameter estimates. RESULTS: A total of 1,207 re-
spondents completed the survey. IRT item parameter estimates (slope and item
characteristic curve thresholds) and item information functions were obtained for
all 95-items. Mean score across all items for the FM sample was 3.68 compared to
the PROMISmeanof 2.12.Maximum information functionwas2 for 22/95 items in
the FM sample, compared to only 2/95 items in the PROMIS sample, indicating
differences in both discriminate ability as well as the difficulty of items for a FM
specific population. CONCLUSIONS:Disease specific item level calibrations of PRO-
MIS items can be estimated. Using the same GRMmethodology as PROMISwewere
able to calculate revised item parameter estimates and information functions.
These estimates can be used to construct improved efficient short-forms or for
application in computer adaptive testing.
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OBJECTIVES: To evaluate the reliability and validity of the Lupus Impact Tracker
(LIT), a patient-based assessment of systemic lupus erythematosus (SLE) disease
impact.METHODS: Reliability and validity of scale scores using the 10 selected LIT
items were evaluated using two datasets (cross-sectional, n253 and longitudinal,
n307) which collected information on quality of life (SF-36), disease activity (SLE-
DAI total score, revised SELENA flare index) and patients’ overall general health
rating (GHR) from LupusPRO©. Internal consistency reliability (ICR) was estimated
in both studies using Cronbach’s alpha. In the longitudinal dataset, reliability was
also evaluated by computing the intra-class correlation between LIT scale scores at
baseline and follow-up. Convergent validity was evaluated by correlating LIT scale
score with SF-36, disease activity and GHR. Construct validity was examined by
known-groups validity (comparing mean scale scores across groups known to dif-
fer on conceptually related criterion measures). Analysis of variance was con-
ducted to compare LIT scale scores across patients stratified by each criterion
measure. Responsiveness was studied using known-groups validity. Specifically,
the magnitude and direction of mean score changes on the LIT scale against
changes in GHR (0-100 scale) were evaluated. RESULTS: The 10 LIT items (concen-
tration, medication side effects, fulfilling family responsibilities, woke up feeling
worn out, pain and aching in body, limited activities due to pain/fatigue, anxiety,
depression, self conscious about appearance, ability to plan activities) showed
good ICR (0.89) and test-retest reliability (0.87). LIT items correlated moderately
(r0.5) with SF-36 domains and summary measures and the GHR. Mean scale
scores differed significantly (p0.05) in the hypothesized direction across groups
stratified by disease activity and GHR. CONCLUSIONS: The Lupus Impact Tracker,
a 10-item PRO, is reliable and valid and offers a practical way of assessing the
impact of lupus on a patient’s life.
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OBJECTIVES: To derive a short form questionnaire from the LupusPRO©, for use in
daily practice to assess the impact of SLE. METHODS: LupusPRO is a 44-item vali-
dated quality of life instrument. To identify the subset of items that would fit a
unidimensional structure, one-factor confirmatory factor analysis (CFA) and item-
to-factor loadings and goodness of fit statistics (Confirmatory Fit Index [CFI], Tucker-
Lewis Index [TLI]) were conducted. Backward stepwise regression methods were
used to eliminate items that showed the weakest relationship to clinical criterion
measures of disease activity (SLEDAI total score, revised SELENA flare index) and
patients’ overall general health ratings (from LupusPRO). Four focus groups were
conducted: patients were asked to rate each item of LupusPRO using a 4-point
importance scale and to identify the “top 15” most important items. RESULTS:
Based on CFA, 21 items fit a unidimensional structure. Both goodness of fit statis-
tics (CFI,TLI) exceeded the recommended threshold of 0.9. All items showed high
factor loadings ranging from 0.76 to 0.91. Backward stepwise regression analyses
resulted in 12 items most highly related to patient and clinical criterion measures.
Of focus group participants, 80% rated the top 15 items as “moderately” or “very”
important (importance ratings  2.3). In total 7 items were selected across the 3
approaches (CFA, backward regression, focus groups). Another 14 were selected
based on results from at least 2 approaches. Items measuring symptoms and pro-
creation were excluded: symptom items did not fit with the intent of the tool;
procreation items would not apply to all patients. Finally, changes in the item
selection based on clinical consensus were made, without losing psychometric
properties. CONCLUSIONS: Using quantitative and qualitative methods, 10 items
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